(Q43039079)

12 November 2017

title

Long-term cohort study of chronic hepatitis C according to interferon efficacy (English)

1 reference

12 November 2017

1 reference

1 reference

5

Keiichi Fujiwara

1 reference

12 November 2017

Daisuke Maruoka

1

1 reference

12 November 2017

Fumio Imazeki

2

1 reference

12 November 2017

Makoto Arai

3

1 reference

12 November 2017

Tatsuo Kanda

4

1 reference

12 November 2017

Osamu Yokosuka

6

1 reference

12 November 2017

publication date

1 February 2012

1 reference

Journal of Gastroenterology and Hepatology

12 November 2017

published in

1 reference

12 November 2017

volume

27

1 reference

12 November 2017

issue

2

1 reference

12 November 2017

page(s)

291-299

1 reference

Global epidemiology of hepatitis C virus infection

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06871.X

10.1111/J.1440-1746.2011.06871.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference